MedTrace Logo

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

NCT00816504 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-09-07

No results posted yet for this study

Summary

This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.

Conditions

  • Focal Segmental Glomerulosclerosis

Interventions

DRUG

Galactose

Oral galactose, 0.2 g/kg/dose twice daily for 28 days

Sponsors & Collaborators

  • Medical College of Wisconsin

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Howard Trachtman, MD · Schneider Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00816504 on ClinicalTrials.gov